Journal issues > Issue 7, November 2019 > Severe neutropenia in an infant after treatment with infliximab during pregnancy

Severe neutropenia in an infant after treatment with infliximab during pregnancy

By: M. Verstraeten MD, C. Verbeke MD, B. De Moerloose MD, PhD

SUMMARY

We describe a 7-month-old girl with severe neutropenia born to a mother treated for ulcerative colitis with infliximab until the 24^th week of pregnancy. Despite the recommendation of using Tumour Necrosis Factor inhibitors (TNFi) only in the first and second trimester of pregnancy, significant levels of TNFi in offspring are possible. Hence, drug-induced neutropenia should be considered in the differential diagnosis of infants with severe neutropenia if these were exposed to TNFi in utero. Moreover, additional information is given on the risk of infection and dysfunctional immune development in these new-borns.

(BELG J HEMATOL 2019;10(7):285–9)

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top